These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
495 related articles for article (PubMed ID: 29609903)
1. Transarterial chemoembolization (TACE) in the management of hepatocellular carcinoma: Results of a French national survey on current practices. Fohlen A; Tasu JP; Kobeiter H; Bartoli JM; Pelage JP; Guiu B Diagn Interv Imaging; 2018 Sep; 99(9):527-535. PubMed ID: 29609903 [TBL] [Abstract][Full Text] [Related]
2. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma. Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378 [TBL] [Abstract][Full Text] [Related]
3. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study. Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680 [No Abstract] [Full Text] [Related]
4. Current trends in the treatment of hepatocellular carcinoma with transarterial embolization: a cross-sectional survey of techniques. Young S; Craig P; Golzarian J Eur Radiol; 2019 Jun; 29(6):3287-3295. PubMed ID: 30350163 [TBL] [Abstract][Full Text] [Related]
5. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752 [TBL] [Abstract][Full Text] [Related]
6. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447 [TBL] [Abstract][Full Text] [Related]
7. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study. Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients. Gomes AS; Monteleone PA; Sayre JW; Finn RS; Sadeghi S; Tong MJ; Britten CD; Busuttil RW AJR Am J Roentgenol; 2017 Oct; 209(4):722-732. PubMed ID: 28705059 [TBL] [Abstract][Full Text] [Related]
9. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC. Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737 [TBL] [Abstract][Full Text] [Related]
10. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study. Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418 [TBL] [Abstract][Full Text] [Related]
11. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting. Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338 [No Abstract] [Full Text] [Related]
12. Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma. Arabi M; BenMousa A; Bzeizi K; Garad F; Ahmed I; Al-Otaibi M Saudi J Gastroenterol; 2015; 21(3):175-80. PubMed ID: 26021777 [TBL] [Abstract][Full Text] [Related]
13. Idarubicin Roth GS; Teyssier Y; Abousalihac M; Seigneurin A; Ghelfi J; Sengel C; Decaens T World J Gastroenterol; 2020 Jan; 26(3):324-334. PubMed ID: 31988592 [TBL] [Abstract][Full Text] [Related]
14. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety. Zhang ZS; Li HZ; Ma C; Xiao YD BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814 [TBL] [Abstract][Full Text] [Related]
15. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study. Wu B; Zhou J; Ling G; Zhu D; Long Q World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma. Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519 [TBL] [Abstract][Full Text] [Related]
17. Risk factors for local recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization with drug-eluting beads (DEB-TACE). Nakano MM; Yamamoto A; Nishida N; Hamuro M; Hamamoto S; Jogo A; Sohgawa E; Kageyama K; Minami T; Miki Y Jpn J Radiol; 2019 Jul; 37(7):543-548. PubMed ID: 31055710 [TBL] [Abstract][Full Text] [Related]